The FDA on June 23, 2017 approved BEVYXXA® for the prophylaxis of Venous ThromboEmbolism (VTE) in adult patients hospitalized for an acute medical illness, who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. BEVYXXA® is a product of Portola Pharmaceuticals.
Bottom Ad
Advertisement
Subscribe
